首页> 外国专利> Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same

Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same

机译:具有速激肽拮抗剂活性的肽,其制备方法和包含该肽的药物组合物

摘要

Amino acid derivs. of formula (I) and their pharmaceutically acceptable salts are new. R1 = vinyl, aryl, heteroaryl, aralkyl, heteroaralkyl, arylvinyl, heteroarylvinyl, aryloxyalkyl, arylalkyloxy, 3-8C cycloalkyl, 3-8C cycloalkyl-alkyl, opt. mono-, di- or tri-Me substd. bicycloheptyl or bicycloheptyl alkyl, etc. In R1, aryl = naphthyl or Ph (this last opt. mono, di or tri-substd. by halogen, trihalo-methyl, alkoxy, alkyl, OH, NO2, alkylcarbonyl or CN); heteroaryl = indolyl (opt. substd. at position 1 with alkyl or benzyl), pyridyl, etc. A1 = Ala, Val, Leu, Ile, Ser, Thr, allo-Thr, Cys, Met, Phe, Trp (opt. N-formyl protected), Tyr, Pro, DPro (e.g. D(3,4)-Pro), Pro(OH) (e.g. Pro(3OH) or Pro(4OH)), A2t, Tpr, Pro(NH2) (e.g. Pro(nH2) or Pro(4NH2)), pGlu, Aib, 2,3-diamino-propionic acid, 2,4-diaminobutyric acid, etc. B = A2NR2R3 or R5; A2 = a lipophilic alpha-amino acid contg. an opt. mono-, di- or tri-substd. Ph, or heteroaryl, cyclohexyl, cyclopentyl, naphthyl or mono- or di(1-3C) alkyl amino, etc. In A2 the substits on Ph = halogen, alkoxy, alkyl, CN or 1-pyrrolidinyl; the chain members in the 1-8 membered chain are CHR4, CO, O, S and/or NR4, etc. R4 = H, alkyl, aryl or aralkyl. In R4, aryl = naphthyl or Ph (this last opt. mono-, di- or tri-substd. with halogen, etc.); R2, R3 = alkyl, arylalkyl, heteroaryl, etc. In R2 and R3, aryl = naphthyl or Ph (this last opt. mono-, di- or tri-substd. by halogen, trihalomethyl, etc.); R5 = a gp. of formula (a) or (b); R6 = aralkyl, diarylalkyl (aryl = Ph or naphthyl and alkyl contains 1-5C), heteroaryl (1-5C)alkyl (heteroaryl - 2-, 3- or 4-pyridyl or 2- or 3-thienyl), etc.; R7 = H or 1-5C alkyl; X = O or H2; Y, Z = H, 1-5C alkyl, 1-5C alkyloxy, benzyloxy (the Ph gp. being opt mono-, di- or tri-substd. with 1-5C alkyl, esp. mono-, di- or tri-substd. with 1-5C alkyl, esp. Me, 1-5C alkoxy, esp. MeO, NMe2, halogen, C3, CN or OCF3) OCF3, halogen, CF3, CN, etc. t = u = 0, t = 1 and u = 0; t = u = 1; t = 2 and u = 0; and if t = 1 and u = 0, R5 can also be a gp. of formula (c); R8 = H and R9 = OH, 1-5C alkoxy, phenyl-(1-5C) alkyloxy, naphthyl (1-5C)alkyloxy or 1-4C alkylcarbonyl; or R8 + R9 together form O or OCH2CH2O; the chirality on C is R or S.
机译:氨基酸衍生。式(I)的化合物及其可药用盐是新的。 R 1 =乙烯基,芳基,杂芳基,芳烷基,杂芳烷基,芳基乙烯基,杂芳基乙烯基,芳氧基烷基,芳基烷氧基,3-8C环烷基,3-8C环烷基-烷基,可选。单,二或三甲基取代。在R1中,芳基=萘基或Ph(最后一个为卤素,三卤代甲基,烷氧基,烷基,OH,NO2,烷基羰基或CN取代的单,二或三取代基);杂芳基=吲哚基(在1位上被烷基或苄基取代),吡啶基等。A1 =丙氨酸,缬氨酸,亮氨酸,离子,丝氨酸,苏氨酸,别-Thr,半胱氨酸,大都会,苯丙氨酸,色氨酸(优化N -甲酰基保护),Tyr,Pro,DPro(例如D(3,4)-Pro),Pro(OH)(例如Pro(3OH)或Pro(4OH)),A2t,Tpr,Pro(NH2)(例如Pro (nH 2)或Pro(4NH 2)),pGlu,Aib,2,3-二氨基丙酸,2,4-二氨基丁酸等。B = A 2 NR 2 R 3或R 5。 A2 =亲脂性α-氨基酸续。一个选择。单,二或三取代。 Ph或杂芳基,环己基,环戊基,萘基或单或二(1-3C)烷基氨基等。在A2中,Ph上的取代基=卤素,烷氧基,烷基,CN或1-吡咯烷基; 1-8元链中的链成员为CHR4,CO,O,S和/或NR4等。R4= H,烷基,芳基或芳烷基。在R4中,芳基=萘基或Ph(最后选择的一元,二元或三元的卤素,等);在R2和R3中,芳基=萘基或Ph(最后一个被卤素,三卤代甲基等单,二或三取代); R2,R3 =烷基,芳基烷基,杂芳基等。 R5 = gp。具有式(a)或(b); R6 =芳烷基,二芳基烷基(芳基= Ph或萘基且烷基含有1-5C),杂芳基(1-5C)烷基(杂芳基-2-,3-或4-吡啶基或2-或3-噻吩基)等; R7 = H或1-5C烷基; X = O或H2; Y,Z = H,1-5C烷基,1-5C烷氧基,苄氧基(Ph gp。优选被1-5C烷基单,二或三取代,尤其是单-,二或三-用1-5C烷基,尤其是Me,1-5C烷氧基,尤其是MeO,NMe2,卤素,C3,CN或OCF3取代)OCF3,卤素,CF3,CN等t = u = 0,t = 1 u = 0; t = u = 1; t = 2且u = 0;如果t = 1且u = 0,则R5也可以是gp。式(c); R8 = H且R9 = OH,1-5C的烷氧基,苯基-(1-5C)的烷氧基​​,萘基的(1-5C)的烷氧基​​或1-4C的烷基羰基;或R 8 + R 9一起形成O或OCH 2 CH 2 O; C上的手性为R或S。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号